Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects

BACKGROUND: Lixisenatide is a once‐daily, prandial, short‐acting glucagon‐like peptide‐1 receptor agonist. Its main antidiabetic effect is to delay gastric emptying to control postprandial plasma glucose excursions. The dose–response relationship of the integrated insulinotropic and gastrostatic res...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Diabetes Metab Res Rev
Prif Awduron: Becker, Reinhard H. A., Stechl, Jens, Steinstraesser, Axel, Golor, Georg, Pellissier, Franck
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2015
Pynciau:
Research Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4744661/
https://ncbi.nlm.nih.gov/pubmed/25773712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/dmrr.2647
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg